Parexel is seeking VA sites for possible participation on a Phase IB/3 study in patients with Follicular Lymphoma

Epizyme, with support by their Contract Research Organization, Parexel is seeking VA sites for possible participation on a Phase IB/3 study in patients with Follicular Lymphoma. Please share this study opportunity with hematologists.  A few details are provided below.

Here is the clinicaltrials.gov link: https://www.clinicaltrials.gov/ct2/show/NCT04224493?term=Epizyme&cond=Follicular+Lymphoma&draw=2&rank=1

A CDA has been executed at the central office level (signed by Dr. Ramoni). This agreement binds all VA Medical Centers and does not require signature by the local medical center’s institutional official. Instead, the only signature that is required is that of the interested investigator- simply acknowledging that s/he has read the CDA and understands the terms.  I have attached a copy of the executed CDA. The 4th page is a “Description of Trial” or DOT.  Please note that in the CDA itself the DOT  is simply an example.  

Therefore, interested investigators must complete the 2nd document (study specific DOT) and sign and return to me. This will allow me to release the protocol and other documents for their further consideration.  Please send any signed DOT’s to me by Thursday  3/19/2020 if at all possible.

Please let me know if you have any questions about the protocol and/or this process.

Krissa

Krissa Caroff, MS

Clinical Trials Facilitator

NAVREF

www.navref.org

(301) 276-0758